Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals ...
Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs) ThecaFlex DRx™ has ...
December 25, 2025, 8:37 PM ESTHealth Care November 30, 2025, 6:53 PM ESTTechnology November 24, 2025, 2:02 PM ESTHealth Care November 19, 2025, 9:57 AM ESTHealth Care November 13, 2025, 4:05 PM ...
Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Biogen has invested ...
Please provide your email address to receive an email when new articles are posted on . Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular ...
CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s ...
Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its chief executive officer said in an interview.
Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results